BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20956959)

  • 81. Hodgkin's Lymphoma - evaluation of patients submitted to Autologous transplantation of hematopoietic cells in the Hematology Service of the Hospital Walter Cantídio - Fortaleza, Brazil.
    Duarte FB; Fernandes MG; Kaufmann J; Barroso KS; Leitão JP; Araujo BS; Costa CM; Quixadá-Medica AT; Holanda JS; Landim SV; Pitombeira MH
    Rev Assoc Med Bras (1992); 2016 Oct; 62 Suppl 1():34-38. PubMed ID: 27982313
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Clinical characteristics of patients with lymphoproliferative disorders after allogeneic hematopoietic stem cell transplant].
    Gu B; Chen GH; Wang Y
    Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1046-9. PubMed ID: 23363801
    [No Abstract]   [Full Text] [Related]  

  • 83. Kikuchi-Fujimoto disease after allogeneic hematopoietic SCT mimicking post transplant lymphoproliferative disorder.
    Lin CC; Yeh SP; Chiang IP; Chiu CF
    Bone Marrow Transplant; 2011 Oct; 46(10):1389-90. PubMed ID: 21113190
    [No Abstract]   [Full Text] [Related]  

  • 84. Clonally identical Hodgkin's disease develops after allogeneic hematopoietic cell transplant for CLL.
    Tseng D; Jones CD; Anderson M; Warnke R; Zehnder JL; Miklos DB
    Bone Marrow Transplant; 2011 Dec; 46(12):1576-8. PubMed ID: 21258419
    [No Abstract]   [Full Text] [Related]  

  • 85. Donor lymphocyte infusion is an effective therapy for relapsed Hodgkin lymphoma after reduced-intensity allogeneic hematopoietic stem cell transplantation.
    Oba U; Koga Y; Suminoe A; Hara T
    Int J Hematol; 2014 Nov; 100(5):511-3. PubMed ID: 25096222
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study.
    Gutman JA; Bearman SI; Nieto Y; Sweetenham JW; Jones RB; Shpall EJ; Zeng C; Baron A; McSweeney PA
    Bone Marrow Transplant; 2005 Sep; 36(5):443-51. PubMed ID: 15995712
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Central nervous system complications after allogeneic hematopoietic stem cell transplantation.
    Chaudhary RK; Dhakal P; Aryal A; Bhatt VR
    Future Oncol; 2017 Oct; 13(25):2297-2312. PubMed ID: 28984145
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Myelofibrosis with myeloid metaplasia in a patient with relapsed Hodgkin's lymphoma who underwent autologous hematopoietic stem cell transplantation.
    Massa FS; Rolón JM; Pavlovsky S
    Hematology; 2007 Dec; 12(6):487-8. PubMed ID: 17852452
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Risk-adapted transplant strategies for high-risk Hodgkin lymphoma: are we there?
    Lewalle P; Wittnebel S
    Curr Opin Oncol; 2016 Sep; 28(5):390-7. PubMed ID: 27467971
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.
    Rosenberg AS; Klein AK; Ruthazer R; Evens AM
    Am J Hematol; 2016 Jun; 91(6):560-5. PubMed ID: 26928381
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Immune-mediated attack in relapsed Hodgkin's lymphoma.
    Corradini P; Farina L
    Lancet; 2005 Jun 4-10; 365(9475):1906-8. PubMed ID: 15936404
    [No Abstract]   [Full Text] [Related]  

  • 92. Adolescent male fertility following reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in non-malignant disorders.
    Zhao J; Beebe K; Magee K; Salzberg D; Stahlecker J; Miller HK; Adams RH; Lipskind S; Walsh A; Mirea L; Ngwube A
    Pediatr Transplant; 2019 Sep; 23(6):e13496. PubMed ID: 31124253
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT.
    Eyre TA; Caillard S; Finel H; Boumendil A; Kothari J; Zimmermann H; Trappe RU; De Wilde V; Tholouli E; Kanfer E; Broom A; Damaj G; Bargetzi M; Kozák T; Hilgendorf I; Crawley C; Kerre T; Trněný M; Bachy E; Robinson S; Montoto S
    Bone Marrow Transplant; 2021 Sep; 56(9):2118-2124. PubMed ID: 33864020
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Hematopoietic stem cell transplantation in patients infected with HIV.
    Serrano D; Miralles P; Balsalobre P; Díez-Martin JL; Berenguer J
    Curr HIV/AIDS Rep; 2010 Aug; 7(3):175-84. PubMed ID: 20549392
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma.
    Singh AK; Porrata LF; Aljitawi O; Lin T; Shune L; Ganguly S; McGuirk JP; Abhyankar S
    Bone Marrow Transplant; 2016 Sep; 51(9):1268-70. PubMed ID: 27111048
    [No Abstract]   [Full Text] [Related]  

  • 96. Impact of body mass index on pulmonary complications in patients with non-Hodgkin lymphoma treated with hematopoietic stem cell transplant.
    Lin C; Lin J; Stavas M; Li S; Canady KJ; Romberger DJ; Loberiza FR
    Leuk Lymphoma; 2015; 56(11):3058-64. PubMed ID: 25739939
    [TBL] [Abstract][Full Text] [Related]  

  • 97. An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial.
    Grigg A; Butcher B; Khodr B; Bajel A; Hertzberg M; Patil S; D'Souza AB; Ganly P; Ebeling P; Wong E
    Bone Marrow Transplant; 2017 Sep; 52(9):1288-1293. PubMed ID: 28628088
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Malignancies after hematopoietic stem cell transplantation: many questions, some answers.
    Deeg HJ; Socie G
    Blood; 1998 Mar; 91(6):1833-44. PubMed ID: 9490664
    [No Abstract]   [Full Text] [Related]  

  • 99. Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression.
    Badar T; Astle J; Kakar IK; Zellner K; Hari PN; Hamadani M
    Br J Haematol; 2020 Jul; 190(2):e98-e101. PubMed ID: 32415780
    [No Abstract]   [Full Text] [Related]  

  • 100. Results of a completely outpatient autologous stem cell transplant program for lymphoma patients receiving reduced-intensity conditioning.
    Jaime-Pérez JC; Hernández-Coronado M; Picón-Galindo E; Salazar-Cavazos L; Gutiérrez-Aguirre CH; Gómez-Almaguer D
    Leuk Lymphoma; 2021 Jul; 62(7):1619-1628. PubMed ID: 33491518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.